


PZ703b

Cat. No.:	HY-115718
CAS No.:	2471970-56-4
Molecular Formula:	C ₈₀ H ₁₀₂ ClF ₃ N ₁₀ O ₁₁ S ₄
Molecular Weight:	1600.43
Target:	PROTACs; Bcl-2 Family
Pathway:	PROTAC; Apoptosis
Storage:	-20°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (62.48 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent		1 mg	5 mg	10 mg
	Concentration	Mass			
	1 mM		0.6248 mL	3.1242 mL	6.2483 mL
	5 mM		0.1250 mL	0.6248 mL	1.2497 mL
	10 mM		0.0625 mL	0.3124 mL	0.6248 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

PZ703b is a Bcl-xL PROTAC degrader that induces apoptosis and inhibits cancer cell proliferation. PZ703b can be used for the research of bladder cancer research^{[1][2]}.

IC₅₀ & Target

VHL Bcl-xL

In Vitro

PZ703b (0-1 μM, 24 h) synergistically inhibits bladder cancer cell proliferation with Mivebresib with a dose-dependent manner and induces apoptosis in bladder cancer cells via the mitochondrial pathway^[1].
 PZ703b (0-1 μM, 48 h) inhibits cell viability of MOLT-4 and RS4;11 cells with IC₅₀ values of 15.9 and 11.3 nM, respectively^[2].
 PZ703b (10 nM, 48 h) induces rapid and durable BCL-XL degradation and apoptosis in MOLT-4 cells through the caspase-3 mediated pathway^[2].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.
 Cell Viability Assay^[1]

Cell Line:	MOLT-4 cell line
Concentration:	10 nM

Incubation Time:	48 hours
Result:	Induced cell apoptosis of MOLT-4 cells.

CUSTOMER VALIDATION

- Biochem Biophys Res Commun. 16 July 2022.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Yi Xu, et al. Mivebresib synergized with PZ703b, a novel Bcl-xl PROTAC degrader, induces apoptosis in bladder cancer cells via the mitochondrial pathway. Biochem Biophys Res Commun. 2022 Oct 1;623:120-126.
- [2]. Pal P, et al. Discovery of a Novel BCL-XL PROTAC Degradere with Enhanced BCL-2 Inhibition. J Med Chem. 2021 Oct 14;64(19):14230-14246.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA